Here are the 10-K annual reports from Inogen Inc (INGN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INGN filings page.
Inogen, Inc. files its annual report describing a respiratory-focused medical technology business built around portable oxygen concentrators, the Simeox airway-clearance device, Voxi 5 stationary oxygen concentrators, and Aurora CPAP masks. The company targets chronic respiratory conditions such as COPD, bronchiectasis and obstructive sleep apnea.
In 2025, Inogen generated $209.8 million of revenue in the United States, with about 45.1% from business-to-business sales, 29.5% from direct-to-consumer sales, and 25.4% from direct-to-consumer rentals. Approximately 39.8% of total 2025 revenue came from outside the United States, sold through distributors and large house accounts in 70 countries.
The report highlights a strategic collaboration with Yuwell to distribute Voxi 5 and Aurora masks in the United States and certain Asian markets, and the 2023 acquisition of Physio‑Assist, which added Simeox and expanded into airway clearance. Rental revenue depends heavily on Medicare programs, which supplied 61.9% of 2025 rental revenue and 9.5% of total revenue. As of December 31, 2025, Inogen employed 753 people worldwide and emphasizes innovation, regulatory compliance, and clinical evidence to support adoption of its products.